Company Filing History:
Years Active: 2014-2016
Title: Innovations by Martin Ingelsson in Neurodegenerative Disorder Treatments
Introduction
Martin Ingelsson is a notable inventor based in Uppsala, Sweden. He has made significant contributions to the field of neurodegenerative disorders through his innovative research and patented inventions. With a total of two patents, Ingelsson's work focuses on antibodies and vaccines aimed at treating and diagnosing α-synuclein-related disorders.
Latest Patents
Ingelsson's latest patents include groundbreaking methods for treating or delaying the onset of neurodegenerative disorders characterized by α-synuclein pathology. One patent describes a method that involves administering an antibody produced from a stabilized soluble α-synuclein oligomer. This antibody is capable of binding to the stabilized soluble α-synuclein oligomer, which has a lower formation rate to a non-soluble aggregated form compared to a non-stabilized soluble oligomer. The disorders targeted by this invention include Parkinson's disease, dementia with Lewy bodies, the Lewy body variant of Alzheimer's disease, and multiple system atrophy. Another patent focuses on a vaccine designed to delay the onset or treat α-synuclein-related disorders, utilizing a therapeutically effective amount of isolated stabilized soluble α-synuclein oligomer.
Career Highlights
Throughout his career, Martin Ingelsson has worked with prominent companies in the neuroscience field, including Bioarctic Neuroscience AB and Bioarctic AB. His research has been pivotal in advancing therapeutic options for patients suffering from neurodegenerative diseases.
Collaborations
Ingelsson has collaborated with notable colleagues such as Lars Lannfelt and Joakim Bergström. Their combined expertise has contributed to the development of innovative solutions in the treatment of neurodegenerative disorders.
Conclusion
Martin Ingelsson's contributions to the field of neurodegenerative disorders through his patents and collaborations highlight his role as a leading inventor in this critical area of research. His work continues to pave the way for new therapeutic approaches that may significantly improve patient outcomes.